Provide feedbackProvide feedback

« Back

Anika Therapeutics licenses U.S. rights to Monovisc to DePuy Mitek

Thursday, December 22 2011 | Comments
Evidence Grade 0 What's This?
Anika Therapeutics Inc. entered into an exclusive, multiyear U.S. licensing and supply agreement with DePuy Mitek Inc. for Monovisc (hyaluronic acid), Anika's investigational treatment for pain in patients with osteoarthritis of the knee.

Under the terms of the agreement, Anika will receive an initial payment of $2.5 million and will be eligible to receive additional regulatory, clinical and sales milestone payments, pending a mutual decision by the two firms to launch the product.

The Food and Drug Administration is reviewing Anika's approval application for Monovisc, a product that has been marketed in other countries since 2008.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.